EcoDrugPlus

Protein Kinase D3

Ensembl ID : ENSDCDG00000026573
Gene Symbol: PRKD3
3 Cross references
218 Possible Orthologues:

Protein Kinase D3

Ensembl ID : ENSDCDG00000003326
Gene Symbol: PRKD3
3 Cross references
207 Possible Orthologues:

Protein Kinase, Dna-Activated, Catalytic Subunit

Ensembl ID : ENSDCDG00000001097
Gene Symbol: PRKDC
3 Cross references
187 Possible Orthologues:

Protein Mono-Adp-Ribosyltransferase Parp3-Like

Ensembl ID : ENSDCDG00000034503
Gene Symbol: LOC114800731
3 Cross references
200 Possible Orthologues:

Protein Phosphatase 3 Catalytic Subunit Alpha

Ensembl ID : ENSDCDG00000030774
Gene Symbol: PPP3CA
3 Cross references
233 Possible Orthologues:

Protein Tyrosine Kinase 2

Ensembl ID : ENSDCDG00000032784
Gene Symbol: PTK2
3 Cross references
247 Possible Orthologues:

Protein Tyrosine Kinase 2 Beta

Ensembl ID : ENSDCDG00000015072
Gene Symbol: PTK2B
1 Cross references
142 Possible Orthologues:

Protein Tyrosine Kinase 2 Beta

Ensembl ID : ENSDCDG00000035654
Gene Symbol: PTK2B
3 Cross references
196 Possible Orthologues:

Protein Tyrosine Kinase 6

Ensembl ID : ENSDCDG00000022408
Gene Symbol: PTK6
3 Cross references
160 Possible Orthologues:

Protein Tyrosine Phosphatase Non-Receptor Type 11

Ensembl ID : ENSDCDG00000002696
Gene Symbol: PTPN11
3 Cross references
253 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSDCDG00000030926
Gene Symbol: PTPRB
3 Cross references
201 Possible Orthologues:

Protein-Serine O-Palmitoleoyltransferase Porcupine-Like

Ensembl ID : ENSDCDG00000003101
Gene Symbol: LOC114798599
3 Cross references
197 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).